Immunome Inc.

Company Overview

Business Model: IMMUNOME, INC. is a biotechnology company focused on the discovery, design, development, manufacturing, and commercialization of first-in-class and best-in-class targeted oncology therapies, primarily antibody-drug conjugates (ADCs) and other oncology therapeutics. The Company aims to build a broad portfolio of differentiated clinical assets to improve outcomes for cancer patients, emphasizing novel or underexplored targets. Its strategy includes leveraging internal ADC expertise, advancing its pipeline, and pursuing selective business development opportunities such as strategic collaborations, alliances, in-licensing, and acquisitions. The Company has not yet generated revenue from product sales.

Market Position: IMMUNOME, INC. operates in the highly competitive pharmaceutical and biotechnology sectors, specifically targeting cancer therapies. The Company differentiates itself through deep expertise in ADC development, including a proprietary TOP1 inhibitor payload (HC74) and optimized linkers, and a strategic focus on novel or underexplored targets to address unmet medical needs. Its leadership team has prior experience in the design, development, and commercialization of cutting-edge targeted cancer therapies, including the first ADCs for Hodgkin and T-cell lymphoma, urothelial cancer, and cervical cancer. Key competitors include large multinational pharmaceutical companies such as Merck KGaA, Merck & Co. Inc., Novartis, Ratio Therapeutics, Perspective Therapeutics, and Sinotau Pharmaceutical Group, among others.

Recent Strategic Developments:

• Varegacestat Acquisition: In March 2024, IMMUNOME, INC. acquired the AL101 and varegacestat programs from Ayala Pharmaceuticals, Inc. for approximately $20.0 million in cash and 2,175,489 shares of common stock (fair value $50.6 million). In December 2025, the Company achieved a $10.0 million development milestone related to positive Phase 3 RINGSIDE trial results for varegacestat.
• ROR1 ADC Acquisition: In January 2024, IMMUNOME, INC. licensed ROR1 ADC technology from Zentalis Pharmaceuticals, Inc. for $15.0 million in cash and 2,298,586 shares of common stock (fair value $23.4 million). This was followed by an asset purchase in October 2024, terminating the license agreement and acquiring the assets for 1,805,502 shares of common stock (fair value $21.0 million). A $5.0 million developmental milestone was achieved in Q4 2024 and paid in Q1 2025.
• BMS License Amendment: In August 2024, IMMUNOME, INC. issued 230,415 shares of common stock (fair value $2.7 million) to Bristol-Myers Squibb Company for an amendment to the assumed BMS License Agreement.
• AbbVie Collaboration Termination: The Collaboration and Option Agreement with AbbVie Global Enterprises Ltd. terminated in July 2025.

Geographic Footprint: IMMUNOME, INC. conducts its primary business operations, including office and laboratory space, in Bothell, Washington, within the greater Seattle area. Clinical trials for its product candidates, such as the Phase 3 RINGSIDE trial for varegacestat, have a global reach, including North America, Europe, Asia, and Australia. The Company holds global commercial rights for varegacestat and plans to commercialize it through an internal organization in the United States, while exploring flexible strategies, including internal teams or strategic collaborations, for international markets like Europe.

Financial Performance

Revenue Analysis

Investment in Growth:

• R&D Expenditure: $177.3 million (2025), $129.5 million (2024), representing a 36.9% increase year-over-year.
• Capital Expenditures: $9.7 million (2025), $7.2 million (2024).
• Strategic Investments:
  • In-process research and development (IPR&D) expenses: $10.0 million (2025, related to Ayala milestone), $152.3 million (2024, related to asset acquisitions from Ayala, Bristol-Myers Squibb Company, Zentalis, and others).
  • Cash paid for IPR&D assets: $6.2 million (2025), $46.3 million (2024).

Business Segment Analysis

IMMUNOME, INC. operates as a single operating and reporting segment focused on the development of targeted oncology therapies. However, the Company provides a breakdown of its direct research and development expenses by program.

Varegacestat

Financial Performance:

• Direct R&D Expense: $52.4 million (+87.3% YoY)
• Key Growth Drivers: Increased clinical trial activities, manufacturing, and consulting efforts associated with the Phase 3 RINGSIDE trial and preparation for the expected NDA submission in Q2 2026.

Product Portfolio: Varegacestat is an investigational, oral, once-daily gamma secretase inhibitor (GSI) for the treatment of desmoid tumors.

Market Dynamics: In December 2025, the global pivotal Phase 3 RINGSIDE trial reported positive topline results, meeting all primary and key secondary endpoints. The Company anticipates submitting a New Drug Application (NDA) in Q2 2026. Varegacestat competes with other treatments for desmoid tumors, including OGSIVEO® (nirogacestat) from Merck KGaA.

Key Results:

• Achieved primary endpoint of progression-free survival, demonstrating an 84% reduction in the risk of disease progression or death versus placebo (HR=0.16, p<0.0001).
• Confirmed objective response rate (ORR) of 56% with varegacestat versus 9% with placebo (p<0.0001).
• Exploratory analysis showed a median best change in tumor volume of -83% versus +11% with placebo.
• Safety profile consistent with the GSI class, with common adverse events including diarrhea (82%), fatigue (44%), rash (43%), nausea (35%), and cough (34%). Ovarian toxicity was reported in 55.6% of premenopausal women.

IM-1021

Financial Performance:

• Direct R&D Expense: $11.0 million (-54.3% YoY)
• Key Growth Drivers: Shift from outsourced to internal resources for program activities and increased clinical trial activities following the initiation of the Phase 1 trial in February 2025, partially offset by timing of outsourced research, manufacturing, and IND-enabling activities.

Product Portfolio: IM-1021 is a Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) antibody-drug conjugate (ADC) that incorporates HC74, the Company's proprietary TOP1 inhibitor payload.

Market Dynamics: Currently in a Phase 1 trial for solid tumors and B-cell lymphoma. In November 2025, objective responses were observed in B-cell lymphoma patients at multiple dose levels, with initial data expected in 2026. ROR1 is a clinically validated target in B-cell lymphoma and an attractive target for select solid tumors. Competitors include Merck & Co. Inc.'s Zilovertamab vedotin (Phase 3) and CStone Pharmaceuticals, Inc.'s CS5001.

Preclinical Data: Presented in October 2024, demonstrating robust anti-tumor activity, including superior activity compared to Zilovertamab vedotin in a mantle cell lymphoma model and complete responses in a patient-derived NSCLC xenograft model. IND clearance was received in December 2024.

IM-3050

Financial Performance:

• Direct R&D Expense: $5.8 million (-56.6% YoY)
• Key Growth Drivers: Increased clinical trial start-up activities in preparation for a Phase 1 trial in early 2026, partially offset by the timing of outsourced research, manufacturing, and IND-enabling activities. The initiation of the Phase 1 trial has been delayed due to third-party diagnostic radiotracer supply.

Product Portfolio: IM-3050 is a Fibroblast Activation Protein (FAP)-targeted lutetium-177 (177Lu) radioligand therapy (RLT) product candidate for the treatment of solid tumors. It is designed with four functional domains: a FAP-specific ligand, a linker, an albumin-binding domain, and a chelator.

Market Dynamics: FAP is broadly expressed in 75% of solid tumors, making it an attractive target. IND clearance was received in April 2025. Competitors in the FAP-targeted RLT space include Novartis, Ratio Therapeutics, Perspective Therapeutics, and Sinotau Pharmaceutical Group.

Preclinical Data: Demonstrated single-dose antitumor activity and tolerability, with substantial tumor regression observed in a glioblastoma mouse model without meaningful weight loss.

Other Direct Research and Development (Includes IM-1617, IM-1340, IM-1335, and early-stage ADCs)

Financial Performance:

• Direct R&D Expense: $43.2 million (+61.3% YoY)
• Key Growth Drivers: Increased manufacturing activities for IM-1617, IM-1340, and IM-1335 in preparation for IND submissions, partially offset by reductions in target identification and outsourced laboratory services due to increased internal resource utilization.

Product Portfolio:

• IM-1617: A potential first-in-class ADC targeting an undisclosed receptor preferentially expressed in colorectal, non-small cell lung, breast, and ovarian cancers. IND submission expected early 2026.
• IM-1340: A potential first-in-class ADC for multiple solid tumors, targeting an underexplored receptor in neuroendocrine, lung, and prostate tumors. IND submission expected mid-2026.
• IM-1335: An ADC for solid tumor indications, designed to optimize safety and efficacy for a target previously pursued by a competitor. IND submission expected late 2026.
• Early-stage ADCs: Numerous programs from internal discovery efforts are anticipated to yield additional IND submissions in 2027 and beyond.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None reported.
• Dividend Payments: IMMUNOME, INC. has not declared or paid cash dividends since its inception and does not expect to do so in the foreseeable future, intending to retain all future earnings to finance business growth and development.

Balance Sheet Position:

• Cash and Equivalents: $653.5 million (as of December 31, 2025).
• Total Debt: No traditional interest-bearing debt disclosed.
• Net Cash Position: $653.5 million.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Operating lease liabilities total $16.9 million in future minimum lease payments, with $1.5 million due in 2026, $2.3 million in 2027, $2.4 million in 2028, $2.4 million in 2029, and $8.3 million in 2030 and thereafter.

Cash Flow Generation:

• Operating Cash Flow: $(190.9) million (2025), $(110.8) million (2024).
• Free Cash Flow: $(200.6) million (2025), $(118.0) million (2024).

Operational Excellence

Production & Service Model: IMMUNOME, INC. primarily relies on third-party contract manufacturers for all preclinical and clinical trial product materials and commercial supplies. The Company produces materials at a laboratory scale only for certain early research and development activities and does not possess internal facilities or capabilities for large-scale manufacturing. It intends to continue this reliance on third parties for manufacturing, packaging, labeling, testing, and release of products for the foreseeable future, expecting these partners to comply with applicable regulations such as cGMP.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturing: Third-party contract manufacturers for antibodies, linkers, payloads, ADCs, small molecules, and radioligand therapies.
• Clinical Development: Third-party clinical investigators, Contract Research Organizations (CROs), clinical data management organizations, and consultants.
• Diagnostic Supply: Relies on a sole supplier for diagnostic radiotracer supply for IM-3050, which has experienced delays.

Facility Network:

• Manufacturing: Relies entirely on third-party contract manufacturing organizations.
• Research & Development: Operates approximately 53,000 square feet of office and laboratory space in Bothell, Washington.
• Distribution: Plans to establish internal commercial capabilities for distribution in the U.S. for varegacestat, if approved, and may use strategic collaborations for international distribution.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: For potential commercialization of varegacestat in the United States, IMMUNOME, INC. plans to build a focused internal commercial organization, including marketing, analytics, market access, and a targeted sales force to reach specialized treatment centers.
• Channel Partners: Outside the United States, the Company anticipates a flexible commercialization strategy, which may include strategic collaborations, distribution arrangements, or other marketing partnerships with third parties in key markets like Europe.

Customer Portfolio:

• Strategic Partnerships: IMMUNOME, INC. has engaged in strategic transactions and license agreements with entities such as Ayala Pharmaceuticals, Inc., Zentalis Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and Purdue Research Foundation for asset acquisitions and intellectual property licensing.

Geographic Revenue Distribution: The Company's current revenue is derived from collaboration agreements, not product sales. Future product revenue, if any, is anticipated from global markets, with initial commercialization efforts for varegacestat planned for the United States and potentially Europe.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The oncology therapeutic market is highly competitive, characterized by rapidly changing standards of care and a significant focus on a limited number of targets among active clinical ADC programs. IMMUNOME, INC. aims to differentiate itself by pursuing novel or underexplored targets. Mergers and acquisitions in the pharmaceutical and biotechnology industries are concentrating resources among fewer competitors.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Varegacestat (Desmoid Tumors): Merck KGaA (successor to SpringWorks Therapeutics, Inc.) with OGSIVEO® (nirogacestat), which received FDA approval in November 2023. Other treatments include surgery, hormonal therapy, cryotherapy, targeted therapy, and chemotherapy.
• IM-1021 (ROR1 ADC): Merck & Co. Inc. with Zilovertamab vedotin (in Phase 3 clinical trial for diffuse large B-cell lymphoma) and CStone Pharmaceuticals, Inc. with a ROR1 ADC program in clinical development.
• IM-3050 (FAP-targeted RLT): Novartis, Ratio Therapeutics, Perspective Therapeutics, and Sinotau Pharmaceutical Group, all developing FAP-targeted radioligand therapies.
• General Oncology: Large multinational pharmaceutical companies such as Immunogen (acquired by AbbVie Inc.), AstraZeneca, Amgen, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech, Inc. (a member of Roche group), Merck & Co. Inc., Novartis, Seagen (acquired by Pfizer), and Johnson & Johnson.

Competitive Response Strategy: IMMUNOME, INC. focuses on designing ADCs against novel or underexplored targets to achieve significant clinical benefit and meaningful market opportunities. The Company optimizes its antibodies for enhanced internalization and tumor localization and prioritizes definitive preclinical experiments for rapid and financially efficient development.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The Company faces substantial competition from other oncology companies, which could develop safer, more effective, or less expensive products. Competitors may also obtain marketing approval more rapidly, establishing strong market positions. Market acceptance of IMMUNOME, INC.'s product candidates, if approved, is uncertain and depends on factors like safety, efficacy, pricing, reimbursement, and the availability of alternative treatments. Technology Disruption: The Company's product candidates are based on novel approaches, targets, and mechanisms of action, carrying inherent risks of failure. Its ADC platform is not yet proven superior to competing technologies. Program Prioritization: Limited financial and other resources may lead to incorrect prioritization decisions, potentially causing the Company to forgo viable opportunities or relinquish valuable rights.

Operational & Execution Risks

Supply Chain Vulnerabilities: IMMUNOME, INC. relies heavily on third-party contract manufacturers and vendors for preclinical, clinical, and potential commercial supplies, some of which may be sole-source. Any limitations, interruptions, or quality issues in supply, or failure of third parties to perform, could delay or disrupt development and commercialization efforts. For example, the IM-3050 program has experienced delays due to third-party diagnostic radiotracer supply. Geographic Concentration: The Company's primary laboratory operations are concentrated in the greater Seattle area, posing risks from natural disasters or other localized disruptions. Capacity Constraints: The Company's manufacturing partners may be unable to scale manufacturing capacity in a timely or cost-effective manner, potentially delaying development and commercialization.

Financial & Regulatory Risks

Market & Financial Risks: IMMUNOME, INC. has a history of significant operating losses and expects to incur substantial losses for the foreseeable future, with no guarantee of achieving profitability. The Company will require substantial additional funds to advance its pipeline and commercialization efforts, and future capital raises may not be available on acceptable terms or at all, potentially leading to delays or termination of programs. Global economic and political conditions, including inflation and trade barriers, could adversely affect financial condition. Regulatory & Compliance Risks: The Company has not yet obtained FDA approval for any product and has limited experience in submitting marketing applications. Clinical trials are expensive, time-consuming, and have uncertain outcomes. Undesirable side effects from product candidates could delay or deny regulatory approval. The IM-3050 program faces additional challenges due to the novelty of Lutetium-177 oncology therapy, including supply chain interruptions for isotopes and limited administration sites. Post-approval, products would be subject to ongoing regulatory obligations and review, potentially incurring significant additional expense or penalties for non-compliance. Unfavorable pricing regulations or third-party coverage and reimbursement policies could harm business prospects.

Geopolitical & External Risks

Geopolitical Exposure: The Company utilizes third-party suppliers and vendors in several countries outside the United States and conducts clinical trials in regions experiencing geopolitical conflicts, such as Israel, exposing it to risks of supply disruption and increased costs. Trade Relations: U.S. government actions, including new tariffs and the BIOSECURE Act (enacted December 18, 2025), which prohibits federal agencies from procuring biotechnology equipment or services from "biotechnology companies of concern," could impact the Company's supply chain and research and development activities, particularly with Chinese vendors.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Antibody-Drug Conjugates (ADCs): IMMUNOME, INC. possesses deep expertise in ADC discovery, design, development, manufacturing, and commercialization. This includes a proprietary TOP1 inhibitor payload, HC74, designed to overcome payload resistance and increase bystander activity, demonstrating superior cytotoxicity compared to DXd in preclinical studies. The Company also develops optimized, proprietary linkers.
• Radioligand Therapy (RLT): Focused on FAP-targeted RLT with IM-3050, an optimized molecule designed to deliver radioactive 177Lu directly to FAP-expressing cells.
• Gamma Secretase Inhibitor (GSI): Varegacestat, an oral, once-daily GSI.

Innovation Pipeline: The Company is advancing a pipeline of three clinical assets (varegacestat, IM-1021, IM-3050) and three preclinical assets (IM-1617, IM-1340, IM-1335), with anticipated IND submissions for the preclinical ADCs in 2026. Internal discovery efforts are generating numerous early-stage ADCs, with opportunities for additional IND submissions in 2027 and beyond. The Company has screened over 1,000 targets, evaluating more than 40 in vitro and over 15 in vivo.

Intellectual Property Portfolio:

• Patent Strategy: IMMUNOME, INC. seeks to protect its proprietary technology, inventions, and improvements through patents, trade secrets, and regulatory protections like orphan drug designations.
• Patent Holdings: As of December 31, 2025, the Company owns or exclusively in-licenses 170 issued or granted patents and 155 pending applications worldwide.
• Key Patent Expirations:
  • Varegacestat: US composition of matter patent expires in 2038 (includes 5 years of expected patent term extension). Other patent applications, if issued, are expected to expire between 2033-2045.
  • IM-1021, IM-3050, IM-1617, IM-1340, IM-1335: Patent applications, if issued, are expected to expire in 2045.

Technology Partnerships:

• Strategic Alliances: Bristol-Myers Squibb Company (BMS License Agreement for AL101 and varegacestat) and Purdue Research Foundation (Purdue License Agreement for FAP-targeting drugs).

Leadership & Governance

Executive Leadership Team

Board Composition: The Board of Directors' audit committee oversees cybersecurity risk management. The Board is divided into three classes, serving staggered three-year terms.

Human Capital Strategy

Workforce Composition:

• Total Employees: 177 full-time employees as of December 31, 2025.
• Skill Mix: 133 employees were engaged in research and development activities as of December 31, 2025.

Talent Management: Acquisition & Retention: The Company's objectives include identifying, recruiting, and retaining a diverse pool of qualified talent. It offers a competitive total rewards package, an annual bonus program based on company and individual performance, and equity incentives to attract, retain, and reward employees.

Environmental & Social Impact

Environmental Commitments: IMMUNOME, INC. is subject to federal, state, and local laws and regulations governing the use, manufacture, storage, handling, and disposal of hazardous and radioactive materials and waste products. The Company believes it is in material compliance with applicable environmental laws.

Business Cyclicality & Seasonality

No material information explicitly stated in the filing regarding business cyclicality or seasonality.

Regulatory Environment & Compliance

Regulatory Framework: IMMUNOME, INC. is subject to extensive U.S. (FDA under FDCA and PHSA) and foreign regulations governing the research, development, testing, manufacturing, approval, and commercialization of drugs and biologics. Varegacestat has received Fast Track and Orphan Drug Designations from both the FDA (November 2023) and EMA (July 2025) for desmoid tumors. The Company may pursue accelerated approval pathways for future product candidates and may require companion diagnostics for certain products.

Trade & Export Controls: The Company is exposed to trade restrictions and changes in trade policies, including the BIOSECURE Act (enacted December 18, 2025), which prohibits U.S. federal agencies from procuring biotechnology equipment or services from "biotechnology companies of concern." This could impact the Company's ability to work with certain third-party vendors located outside the U.S.

Legal Proceedings: IMMUNOME, INC. is not currently a party to any material legal proceedings.

Tax Strategy & Considerations

Tax Profile: IMMUNOME, INC. has incurred significant operating losses and has recorded a full valuation allowance against its net deferred tax assets. As of December 31, 2025, the Company had $277.2 million in federal and $97.0 million in state net operating loss (NOL) carryforwards. Federal NOLs generated from 2018-2025 ($260.2 million) do not expire but are limited to offsetting 80% of taxable income. The Company also had $15.3 million in federal and $0.2 million in state R&D tax credits. The "One Big Beautiful Bill Act" (OBBBA), enacted July 4, 2025, allows for immediate expensing of domestic Section 174 (R&D) costs starting in 2025.

Insurance & Risk Transfer

Risk Management Framework: IMMUNOME, INC. maintains insurance coverage, including cybersecurity insurance, at levels it deems appropriate for its business. However, it acknowledges that clinical trial and product liability insurance is becoming increasingly expensive, and environmental liability coverage may be inadequate for all potential claims.